drugset / Trial / NCT05660538
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2023-10-12
- Completion
- 2023-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pregabalin | Small molecule | 100 mg | Oral |
| Subject | Suzetrigine | Small molecule | 23 mg | Oral |
| Subject | Suzetrigine | Small molecule | 46 mg | Oral |
| Subject | Suzetrigine | Small molecule | 69 mg | Oral |